Nuveen LLC Takes Position in Embecta Corp. $EMBC

Key Points

• Nuveen LLC acquired 181,472 shares of Embecta Corp. for approximately $2.3 million, representing a 0.31% stake in the company.
• Embecta recently reported a quarterly earnings per share (EPS) of $1.12, exceeding analyst expectations by $0.35, with revenue of $295.5 million for the quarter.
• The company declared a quarterly dividend of $0.15, translating to an annualized yield of 4.1%, with a payout ratio of 41.96%.

Nuveen LLC purchased a new position in Embecta Corp. (NASDAQ:EMBC - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 181,472 shares of the company's stock, valued at approximately $2,314,000. Nuveen LLC owned approximately 0.31% of Embecta at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of EMBC. Deerfield Management Company L.P. Series C boosted its stake in Embecta by 19.8% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 3,270,535 shares of the company's stock worth $67,537,000 after purchasing an additional 540,192 shares in the last quarter. Jefferies Financial Group Inc. lifted its stake in shares of Embecta by 60.1% in the first quarter. Jefferies Financial Group Inc. now owns 573,000 shares of the company's stock worth $7,306,000 after buying an additional 215,000 shares in the last quarter. Ancora Advisors LLC lifted its stake in shares of Embecta by 275.9% in the fourth quarter. Ancora Advisors LLC now owns 254,156 shares of the company's stock worth $5,248,000 after buying an additional 186,550 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new position in Embecta in the 1st quarter valued at approximately $1,071,000. Finally, Dimensional Fund Advisors LP lifted its position in Embecta by 14.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 566,993 shares of the company's stock valued at $11,708,000 after acquiring an additional 73,165 shares in the last quarter. Institutional investors own 93.83% of the company's stock.

Embecta Trading Up 1.0%

EMBC stock traded up $0.14 during trading on Tuesday, reaching $14.62. The stock had a trading volume of 405,489 shares, compared to its average volume of 600,066. Embecta Corp. has a 52 week low of $9.20 and a 52 week high of $21.48. The stock's 50 day moving average is $11.51 and its two-hundred day moving average is $11.86. The firm has a market cap of $855.05 million, a PE ratio of 10.22, a PEG ratio of 0.80 and a beta of 1.11.

Embecta (NASDAQ:EMBC - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.35. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. The firm had revenue of $295.50 million for the quarter, compared to analysts' expectations of $278.15 million. During the same quarter in the prior year, the business earned $0.74 EPS. The business's quarterly revenue was up 8.4% on a year-over-year basis. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. On average, research analysts anticipate that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 29th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date of this dividend is Friday, August 29th. Embecta's dividend payout ratio (DPR) is currently 41.96%.

Analyst Ratings Changes

Several research firms recently issued reports on EMBC. BTIG Research set a $25.00 price objective on Embecta and gave the company a "buy" rating in a research report on Friday, May 23rd. Wall Street Zen raised Embecta from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Zacks Research raised Embecta from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 26th. Finally, Mizuho lowered their target price on shares of Embecta from $13.00 to $12.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.00.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.